Open-label, Multicenter Phase II Study to Investigate the Efficacy, Safety, and Tolerability of the Bispecific T-cell Engager (BiTE) MT103 in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia

Trial Profile

Open-label, Multicenter Phase II Study to Investigate the Efficacy, Safety, and Tolerability of the Bispecific T-cell Engager (BiTE) MT103 in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Sponsors Amgen; Micromet Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Dec 2016 Results assessing Blinatumomab associated Neurologic Events in NCT00274742, NCT00560794, NCT01209286, NCT01471782, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 12 May 2016 Results (pooled analysis of this and other five studies) assessing PK and PD of blinatumomab published in the Clinical Pharmacokinetics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top